Success! The link has been copied to your clipboard.
Current Guidelines for Management of Chronic Kidney Disease and Diabetes
Feature Story | Published: December 10, 2020

Patient Care
We deliver high-quality care with innovation and empathy.
We deliver high-quality care with innovation and empathy.
PRACTICE SUPPORT
Products
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Insights
Our Company
More
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Success! The link has been copied to your clipboard.
Feature Story | Published: December 10, 2020
Released just ahead of American Diabetes Month 2020, Kidney Disease: Improving Global Outcomes (KDIGO) published guidelines highlighting improvements for those struggling with diabetes and Chronic Kidney Disease (CKD) – representing the first comprehensive guidelines on this subject.
The guidelines include 12 recommendations for patient care, as well as 48 practice points for clinicians dealing with diabetes and CKD. The five chapters of the publication, “KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease,” focus on comprehensive care, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and integrated care approaches to management.
KDIGO addresses Type 1 and Type 2 Diabetes, while also focusing on different severities of CKD, including patients on dialysis or transplant recipients. Overall, the guidance is patient centric and emphasizes general well-being and prevention of kidney failure. It builds upon prior guidelines by offering advice specific to diabetes management and recommends the use of promising therapies called SGLT2 inhibitors.
According to the KDIGO guidelines, diabetes affects eight percent of the world’s population, more than 450 million people, but the number is projected to grow in the coming years. Around 40 percent of people living with diabetes are likely to develop CKD, which can potentially lead to kidney failure.
"These new guidelines provide an important roadmap for earlier interventions and diabetes management that can help slow the progression of chronic kidney disease," said Dr. Dugan Maddux, Vice President of Kidney Disease Initiatives at Fresenius Medical Care North America. "It’s clear that education and awareness remain critical to improving outcomes, and new therapies also show great promise in slowing the progression of CKD. These recommendations should absolutely be read and implemented by both primary care physicians and nephrologists.”
The report’s Executive Summary provides specific highlights and summaries of these guidelines for treating patients with diabetes and CKD that include:
© 2006-2023 Fresenius Medical Care. All Rights Reserved.